GLIAGEN LLC, DEVELOPER OF TECHNOLOGIES USED TO TREAT NEURODEGENERATIVE DISEASES
GliaGen is focused on the development of novel diagnostic and therapeutic technologies
specifically tailored to treat neurodegenerative diseases.
GliaGen is developing novel treatments for neuroaffective disorders including Multiple
Sclerosis, Alzheimers, and Parkinsons; including neurotrauma such as spinal cord
The Quincy, Mass.-based company has secured platform technology developed by Dr.
Leon Carlock and Dr. Maria Cypher at the Center for Molecular Medicine and Genetics,
Wayne State University School of Medicine.
In addition to commercializing the patent pending technology, the WSU spinoff will
also support further research at Wayne State.
Center for Molecular Medicine and Genetics • Wayne State University School of Medicine
• 3127 Scott Hall • 540 East Canfield • Detroit, MI 48201. Administrative Office:
(313) 577-5323 Fax: (313) 577-5218 • Email: firstname.lastname@example.org • Webmaster:
GLYTAG, LLC, INNOVATIVE DRUG TARGETING SYSTEM FINDS NEW WAY TO FIGHT CANCER
GlyTag has developed a novel drug targeting system that increases a drug’s therapeutic
efficacy while reducing its toxicity to non-targeted cells and tissues. Dr. Jeff
Loeb of Wayne State University has developed this technology and is working with
the WSU Office of Technology Transfer as GlyTag moves forward in its operations.
The GlyTag system takes advantage of one of nature’s own methods of targeting growth
factors to specific cells in the body through unique cell surface heparin-sulfate
A “GlyTag” is a polypeptide sequence specifically designed to target recombinant
proteins or other macromolecules to specific cells in the body.
GlyTag is currently completing pre-clinical
testing on a prototype GlyTag fusion protein for treating breast
To date, this drug has out-performed the same drug without a GlyTag. For more information visit:http://www.glytag.com